Aviado · Research
Longevity Daily
Monday, May 4, 2026
Listen
Today's Brief
Today's strongest stories share a theme: the immune system drives how well — and how long — you age. Peter Attia's new AMA is must-listen, covering dementia prevention, NAD supplements, and heart disease strategy in one dense hour. New research reframes Alzheimer's as immune misfiring against your own DNA, while a related piece pins STING overactivation as the specific trigger. Aviado's Pycnogenol analysis and new evidence classifying microplastics as biological-aging accelerators round out a strong edition.
10 stories5 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Why Your Brain's Immune System May Be Mistaking Your Own DNA for a Virus — and Driving Dementia
A new review in the Journal of Molecular Neuroscience argues that Alzheimer's is essentially a case of sterile autoimmunity: the brain's innate immune system misidentifies fragments of your own DNA and ancient retroviral remnants (LINE-1, HERVs) as active pathogens, triggering a chronic interferon response. This "ghost war" transforms microglia and astrocytes into senescent, inflammatory cells that release a toxic secretory profile and systematically destroy synapses — a mechanism that also explains why APOE4 carriers are disproportionately vulnerable. The framework points to two emerging therapeutic strategies already in early human trials: repurposing HIV antivirals (NRTIs) to block retrotransposition, and deploying senolytics to clear dysfunctional glial cells. For the health-savvy reader, this is a compelling explanation of why amyloid-clearing drugs keep failing.
Read more →Protein Aggregation Triggers a Hidden Immune Switch That Drives Alzheimer's Neuroinflammation
Researchers have identified how protein buildup in Alzheimer's-affected brains hijacks STING — a key immune early-warning protein — locking it into chronic overactivation through a chemical modification called S-nitrosylation. In mouse models, blocking this specific change substantially reduced neuroinflammation, pointing to a therapeutic target that sits upstream of amyloid plaques. This matters because it adds mechanistic precision to the emerging view that inflammation, not plaque, is the proximate driver of neurodegeneration — and that STING inhibition may be worth pursuing alongside or instead of amyloid-targeting approaches.
Read more →Supplements & Compounds
Pycnogenol Ranked #1 for Mild Cognitive Impairment — But Its Blood Sugar Response Varies 4x Between People
A global analysis of 19 cognitive interventions has placed Pycnogenol at the top for mild cognitive impairment — but Aviado's deep-dive reveals a critical wrinkle: its glucose impact varies up to 400% between individuals. If your fasting glucose or HbA1c is already elevated, you're likely to see meaningful metabolic improvements alongside cognitive benefits; if your numbers are normal, the blood sugar effects may be negligible. The evidence-backed protocol is 100–150 mg daily with food, with baseline and 12-week glucose testing recommended to personalize your response.
Read the full Aviado analysis →Research & Papers
The Thymus Is More Than a Childhood Organ — New Research Casts It as a Master Regulator of Longevity
Long dismissed as biologically obsolete after adolescence, the thymus is being reclassified as a central regulator of immune aging — with a growing body of research linking its functional decline to accelerated biological aging and increased cancer susceptibility across the lifespan. New evidence suggests that thymus health shapes how well the immune system clears senescent cells and detects early malignancies well into adulthood, not just during childhood development. This repositions thymus regeneration — through peptides, growth factors, or pharmacological means — as a serious target for longevity interventions, with several programs now in active research.
Read more →Microplastics Are Being Reclassified as "Gerontogens" — Environmental Accelerators of Biological Aging
A new review in the Journal of Xenobiotics argues that our lifelong accumulation of micro- and nanoplastics (MNPs) acts as a systemic accelerator of biological aging — coining them "gerontogens," a class of environmental exposures that speed up the aging process through chronic inflammation, mitochondrial disruption, and epigenetic dysregulation. Unlike traditional toxicology framing, this review positions MNPs not as occasional hazards but as a continuous, compounding burden embedded throughout the human exposome. If this framework holds, reducing plastic contact in food, water, and cookware may be one of the more underappreciated — and actionable — longevity levers available today.
Read more →Plasma Exchange Within 24 Hours of a Heart Attack Nearly Eliminates Cardiac Fibrosis in Aging Mice
Presented at the Berkeley Longevity Conference by Michael Conboy's lab, a just-published paper shows that therapeutic plasma exchange (TPE) administered within 24 hours of a heart attack in aged mice almost completely prevented cardiac fibrosis and tissue damage. The mechanism mirrors prior heterochronic parabiosis findings — diluting pro-aging blood factors while restoring youthful signaling — but in a clinically deployable intervention rather than experimental blood sharing. This is a mouse study, so human translation remains unproven, but the effect size is striking and human TPE trials for aging-related conditions are already underway.
Read more →Lifestyle & Nutrition
Peter Attia's AMA #84: Dementia Risk Reduction, NAD Supplements, Heart Disease Prevention, and More
In his latest subscriber AMA, Peter Attia tackles a dense and highly actionable lineup — using family health history as a precision risk tool, preventing heart disease before symptoms appear, and evaluating the current evidence base for NAD supplementation in longevity. He also covers strength training efficiency (how to get more from less time), dementia risk reduction strategies, and the often-overlooked role of hydration in metabolic health. The section on metabolic health ties together several pillars of the Protocol framework in practical, applicable terms. If you follow Attia's work — and our reader profile suggests you do — this episode warrants your full attention.
Read more →A New Longevity Readiness Tool Challenges the Idea That Planning for Old Age Is Just About Money
As the oldest millennials turn 45 and the oldest Gen Xers hit 60, a new assessment tool asks whether Americans are prepared to thrive — not just survive — in the decades ahead. Unlike standard retirement calculators, it evaluates physical health, social connection, purpose, and cognitive readiness alongside financial savings. For our audience, this is a useful reframe: longevity planning means integrating your health protocol with your entire life infrastructure, not just your investment portfolio.
Read more →Industry & Policy
FDA-Cleared Bone Density Device Osteoboost Launches Nationwide After Trials Show Reduced Bone Loss
Osteoboost, a wearable vibration device targeting bone density loss in postmenopausal women, has launched nationally following FDA clearance. Clinical trials demonstrated significant reductions in both bone density and bone strength loss with no serious adverse events — a meaningful result for a condition affecting over 10 million Americans that carries major fracture and mobility risk. Bone health is increasingly recognized alongside muscle mass and cardiovascular fitness as a longevity-critical metric worth monitoring and protecting from midlife onward.
Read more →Longevity Drug Trial Launches for Senior Dogs — and the Insulin-Sensitivity Mechanism Has Human Implications
The first patient — an 11-year-old Whippet named Boo — has been dosed in a clinical trial for LOY-002, a drug designed to restore insulin sensitivity in aging dogs and extend healthy lifespan across most breeds. The mechanism is directly relevant to human aging research: declining insulin sensitivity in older tissues impairs organ function across multiple systems, and reversing it is a recognized longevity target. While this is a veterinary study, the biological logic is translatable and the trial's design rigor will generate data worth watching for human longevity drug development.
Read more →